PuSH - Publication Server of Helmholtz Zentrum München

Bardou, O.* ; Menou, A.* ; François, C.* ; Duitman, J.W.* ; von der Thüsen, J.H.* ; Borie, R.* ; Sales, K.U.* ; Mutze, K. ; Castier, Y.* ; Sage, E.H.* ; Liu, L.* ; Bugge, T.H.* ; Fairlie, D.P.* ; Königshoff, M. ; Crestani, B.* ; Borensztajn, K.S.*

Membrane-anchored serine protease matriptase is a trigger of pulmonary fibrogenesis.

Am. J. Respir. Crit. Care Med. 193, 847-860 (2016)
Publ. Version/Full Text Postprint Research data DOI PMC
Open Access Green
RATIONALE: Idiopathic Pulmonary fibrosis (IPF) is a devastating disease, which remains refractory to current therapies. OBJECTIVES: To characterize the expression and activity of the membrane-anchored serine protease matriptase in IPF in humans and unravel its potential role in human and experimental pulmonary fibrogenesis. METHODS: Matriptase expression was assessed in tissue specimens from IPF patients versus controls using qRT-PCR, immunohistochemistry and Western blotting, while matriptase activity was monitored by fluorogenic substrate cleavage. Matriptase-induced fibroproliferative responses and the receptor involved were characterized in human primary pulmonary fibroblasts by Western blot, viability and migration assays. In the murine model of bleomycin-induced pulmonary fibrosis, the consequences of matriptase depletion, either by using the pharmacological inhibitor camostat mesilate, or by genetic down regulation using matriptase hypomorphic mice, were characterized by quantification of secreted collagen and immunostainings. MEASUREMENTS AND MAIN RESULTS: Matriptase expression and activity were upregulated in IPF and bleomycin-induced pulmonary fibrosis. In cultured human pulmonary fibroblasts, matriptase expression was significantly induced by TGF-β. Further, matriptase elicited signaling via Protease-Activated Receptor-2 (PAR-2), and promoted fibroblast activation, proliferation and migration. In the experimental bleomycin model, matriptase depletion, by the pharmacological inhibitor camostat mesilate or by genetic down-regulation, diminished lung injury, collagen production and TGF-β expression and signaling. CONCLUSIONS: These results implicate increased matriptase expression and activity in the pathogenesis of pulmonary fibrosis in human IPF and in an experimental mouse model. Overall, targeting matriptase, or treatment by camostat mesilate, which is already in clinical use for other diseases, may represent potential therapies for IPF.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Idiopathic Pulmonary Fibrosis ; Matriptase ; Camostat Mesilate ; Fibroblast ; Protease-activated Receptor-2; Proteinase-activated Receptor-2; Hepatocyte Growth-factor; Pancreatic Fibrosis; Inhibitor Camostat; Lung Fibrosis; Factor Xa; Tgf-beta; In-vitro; Cell; Fibroblasts
ISSN (print) / ISBN 1073-449X
e-ISSN 1535-4970
Journal American Journal of Respiratory and Critical Care Medicine
Quellenangaben Volume: 193, Issue: 8, Pages: 847-860 Article Number: , Supplement: ,
Publisher American Thoracic Society
Publishing Place New York
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute of Lung Health and Immunity (LHI)